Xencor (XNCR) Expected to Announce Quarterly Earnings on Tuesday

Xencor (NASDAQ:XNCR - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Xencor to post earnings of ($0.81) per share and revenue of $17.14 million for the quarter.

Xencor Stock Performance

Shares of XNCR stock traded down $0.05 during trading hours on Friday, hitting $15.74. The stock had a trading volume of 459,848 shares, compared to its average volume of 503,401. The firm has a market capitalization of $1.10 billion, a PE ratio of -4.92 and a beta of 0.70. Xencor has a twelve month low of $15.31 and a twelve month high of $27.24. The stock's 50 day moving average is $20.38 and its 200 day moving average is $20.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on XNCR. Wells Fargo & Company began coverage on Xencor in a research note on Thursday, December 12th. They set an "overweight" rating and a $37.00 price target for the company. Piper Sandler upgraded Xencor from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. JPMorgan Chase & Co. upped their price target on Xencor from $27.00 to $28.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. BMO Capital Markets restated an "outperform" rating and set a $34.00 price target (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Wedbush restated an "outperform" rating and set a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Xencor has an average rating of "Buy" and a consensus target price of $34.88.

Insiders Place Their Bets

In other news, Director Alan Bruce Montgomery sold 1,421 shares of Xencor stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the transaction, the director now owns 9,140 shares of the company's stock, valued at $247,054.20. The trade was a 13.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.23% of the stock is currently owned by company insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.